Related Experiment Video
Updated: Aug 9, 2026
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice
R Veitia1, M C Bissery, C Martinez
1Unité d'Immunogénétique Humaine, Institut Pasteur, Paris, France.
Abstract:
Docetaxel is a new taxoid with clinical activity in breast and lung cancer. Using docetaxel-sensitive and -refractory mammary and pancreatic murine tumours, as well as human-derived neoplasms, we investigated if a determinant of docetaxel sensitivity could be found at the level of its mechanism of action. Because microtubules represent the cellular targets of the drug, we studied their heterogeneity in the tumour models to try to explain the differences in drug sensitivity. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of the expression of microtubular components showed that levels of Mbeta4-tubulin and Tau mRNAs were higher in the murine sensitive neoplasms than in the refractory ones. It was also found that Tau protein levels differed markedly among the tumours. In the human-derived sensitive neoplasm, beta-tubulins and some Tau isoforms were found to be more abundant than in the resistant one. Western blot analysis of MAP2 revealed the presence of several immunoreactive species. Some of these polypeptides were also found in higher amounts in the docetaxel-sensitive tumours. The possible meaning of these correlations is discussed in connection with the regulation of microtubule dynamics.
Insights
Docetaxel sensitivity in tumors may be linked to microtubule components. Higher levels of Mbeta4-tubulin, Tau mRNA, and Tau protein were found in docetaxel-sensitive tumors, suggesting a role in drug response.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Docetaxel is a taxoid chemotherapy agent with demonstrated efficacy in breast and lung cancers.
- Understanding docetaxel resistance mechanisms is crucial for improving patient outcomes.
- Microtubules are the primary cellular targets of docetaxel.
Purpose of the Study:
- To investigate potential determinants of docetaxel sensitivity at the molecular level.
- To explore the relationship between microtubule component expression and docetaxel response in various tumor models.
- To identify specific microtubule-related factors influencing docetaxel efficacy.
Main Methods:
- Utilized docetaxel-sensitive and -refractory murine mammary and pancreatic tumors, along with human-derived neoplasms.
- Employed reverse transcription-polymerase chain reaction (RT-PCR) to analyze mRNA expression of microtubular components.
- Conducted Western blot analysis to assess protein levels of microtubule-associated proteins (MAPs) like MAP2.
Main Results:
- Higher levels of Mbeta4-tubulin and Tau messenger RNA (mRNA) were observed in docetaxel-sensitive murine tumors compared to refractory ones.
- Significant variations in Tau protein levels were detected across different tumor models.
- Docetaxel-sensitive human tumors exhibited greater abundance of beta-tubulins and specific Tau isoforms compared to resistant tumors.
- Increased amounts of certain MAP2 polypeptides correlated with docetaxel sensitivity.
Conclusions:
- Microtubule component heterogeneity, including Mbeta4-tubulin, Tau, and MAP2, may play a role in determining docetaxel sensitivity.
- The findings suggest a correlation between elevated levels of specific microtubule proteins and enhanced response to docetaxel.
- Further research into microtubule dynamics regulation could elucidate novel therapeutic strategies for overcoming docetaxel resistance.
